Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
We examined the effect of intravenously infused glucagon-like peptide 1 (GLP-1) on subjective appetite sensations after an energy-fixed breakfast, and on spontaneous energy intake at an ad libitum lunch. 20 young, healthy, normal-weight men participated in a placebo-controlled, randomized, blinded, crossover study. Infusion (GLP-1, 50 pmol/ kg.h or saline) was started simultaneously with initiation of the test meals. Visual analogue scales were used to assess appetite sensations throughout the experiment and the palatability of the test meals. Blood was sampled throughout the day for analysis of plasma hormone and substrate levels. After the energy-fixed breakfast, GLP-1 infusion enhanced satiety and fullness compared with placebo (treatment effect: P < 0.03). Furthermore, spontaneous energy intake at the ad libitum lunch was reduced by 12% by GLP-1 infusion compared with saline (P = 0.002). Plasma GLP-1, insulin, glucagon, and blood glucose profiles were affected significantly by the treatment (P < 0.002). In conclusion, the results show that GLP-1 enhanced satiety and reduced energy intake and thus may play a physiological regulatory role in controlling appetite and energy intake in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 RA increase satiety, reduce food intake and delay gastric emptying whilst they also stimulate insulin release and inhibit glucagon secretion in a glucose-dependent manner (Fig. 1) [17, 18].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Short-term studies have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1RA) induce weight loss by promoting satiety and reducing hunger16–19.”
From Exploratory analysis of eating-and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, non-clinical and clinical studies have demonstrated increased satiety, reduced food intake and subsequent reductions in body weight following administration of GLP-1,7, 8”
From Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults (2014) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), the latter has been established as having therapeutic potential for reducing elevated plasma glucose (1, 2) and body weight (3), while the former has been unable to either stimulate insulin secretion (1) or lower plasma glucose effectively in type 2 diabetes (T2D) (4).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [3]
In the citing paper
“GLP-1 receptor agonists (GLP-1RA) have been shown to promote weight loss and decrease liver fat [28,29] (Figure 1).”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [29]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1975) · Journal of AOAC INTERNATIONAL · doi:10.1093/jaoac/58.5.1085 · Cited by 19,795
(1974) · Elsevier eBooks · doi:10.1016/b978-0-12-091304-6.x5001-0 · Cited by 6,755
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Self-citationScrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Items 801–900 of 1,003
Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes
Hedrington, M. S., Tsiskarishvili, A., & Davis, S. N. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1439014 · Cited by 20
Ryan, C. M., Khoo, W. Y. H., Stewart, A. C., O’Keefe, S. F., Lambert, J. D., & Neilson, A. P. (2017) · Food & Function · doi:10.1039/c6fo01730d · Cited by 22
Gut-Brain Neuropeptides in the Regulation of Ingestive Behaviors and Obesity.
Crowell, M. D., Decker, G. A., Levy, R. L., Jeffrey, R., & Talley, N. J. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00832.x · Cited by 23
“Four studies demonstrated that energy intake was significantly reduced following the GLP-1 infusion compared with saline (62, 64, 66, 67).”
Kałas, M., Stępniewska, E., Gniedziejko, M., Leszczyński-Czeczatka, J., & Siemiński, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093122 · Cited by 24
“It is achieved by activating GLP-1 receptors, which reduce food intake, body weight, and stimulate insulin secretion in a glucose-dependent manner [61,74].”
The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight
Melvin, A., le Roux, C. W., & Docherty, N. G. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0599-9 · Cited by 24
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Blüher, M., Ceriello, A., Davies, M., Rodbard, H., Sattar, N., Schnell, O., Tonchevska, E., & Giorgino, F. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.330 · Cited by 20
“117 Further, GLP-1 RAs target the gastrointestinal tract and slow gastric emptying, which in turn delays intestinal glucose absorption.”
Las hormonas gastrointestinales en el control de la ingesta de alimentos
Álvarez-Crespo, M., González-Matías, L. C., Gil‐Lozano, M., Paz, S. F., Romaní‐Pérez, M., Gago, E. M., & Ferrer, F. M. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)71946-1 · Cited by 30
Hata, T., Mera, Y., Tadaki, H., Kuroki, Y., Kawai, T., Ohta, T., & Kakutani, M. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01368.x · Cited by 20
Is the GLP-1 system a viable therapeutic target for weight reduction?
Tong, J., & Sandoval, D. A. (2011) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-011-9170-8 · Cited by 23
“In a randomized, blinded, placebo-controlled crossover study, short-term intravenous (IV) infusion of GLP-1(7-36 amide) that increases plasma concentration of total GLP-1 to pharmacological levels (60–90 pmol/L) in healthy normalweight males enhanced satiety and fullness as well as reduced spontaneous food intake by 1…”
BackgroundEndoscopic Procedures for Weight Loss
Brunaldi, V., & Neto, M. G. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00450-0 · Cited by 20
Tee, C. C. L., Cooke, M. B., Chong, M. C., Yeo, W. K., & CAMERA, D. M. (2022) · Sports Medicine · doi:10.1007/s40279-022-01782-0 · Cited by 21
“Glucagon-like peptide-1 can promote satiety, suppress energy intake, and subsequently prevent weight gain in both human and mouse models [120, 121].”
BackgroundLee, Y., Kwon, M. K., Kang, E. S., Park, Y. M., Choi, S. H., Ahn, C. W., Kim, K., Park, C. W., Soo, B., Kim, S. W., et al. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1153 · Cited by 20
The GLP‐1 system as a therapeutic target
Edwards, M. C. B. (2005) · Annals of Medicine · doi:10.1080/07853890510037400 · Cited by 19
“Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.”
BackgroundInfluentialE. Näslund, J. B. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520121133 · Cited by 15
Self-citationReed, J., Bain, S. C., & Kanamarlapudi, V. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415934 · Cited by 24
“32,112 The ability of GLP-1 to stimulate insulin secretion is dependent on high glucose levels, as this hormone does not induce insulin secretion in the presence of low blood glucose.”
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Self-citationBorer, K. T., Lin, P., & Wuorinen, E. C. (2021) · Nutrients · doi:10.3390/nu13124342 · Cited by 18
“Glucagon-like peptide-1 (GLP-1) [19] and peptide YY (PYY) [20] signal satiety [21], a reduced urge to eat after completion of a meal [8], They are released from the distal ileum and colon 2–3 h after eating [22].”
BackgroundWatkins, J. D., Carter, S., Atkinson, G., Koumanov, F., Betts, J. A., Holst, J. J., & Gonzalez, J. T. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155375 · Cited by 23
Self-citationGriffin, J. D., Zhu, Y., Reeves, A., Buhman, K. K., & Greenberg, A. S. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101918 · Cited by 20
The therapeutic potential of GPR43: a novel role in modulating metabolic health
Cornall, L. M., Mathai, M. L., Hryciw, D. H., & McAinch, A. J. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1419-9 · Cited by 21
Drugs to treat obesity: do they work?
Kim, S. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133388 · Cited by 20
Maurer, L., Mai, K., Krude, H., Haynes, J., Weygandt, M., & Spranger, J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.014 · Cited by 21
“We choose to investigate GLP-1, since this gut-derived, postprandially released peptide has been identified as potentially satiety-promoting hormone reducing subjective appetite sensations and spontaneous energy intake [12].”
Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.009 · Cited by 21
de Grave, X. B., Saltzmann, J., Laurain, J., Rodríguez, M. Á., Molist, F., Dänicke, S., & dos Santos, R. R. (2021) · Toxins · doi:10.3390/toxins13010037 · Cited by 18
“This gut hormone is also released in response to the presence of nutrients in the intestine and, when released, it will inhibit food intake in humans [38].”
BackgroundProgressos recentes e novas perspectivas em farmacoterapia da obesidade
Faria, A. M., Mancini, M. C., de Melo, M. E., Cercato, C., & Halpern, A. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000600003 · Cited by 30
Innovative metabolic operations
COHEN, R. V., Caravatto, P. P. D. P., & Petry, T. B. Z. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.02.034 · Cited by 21
Pinelli, N. R., Jantz, A. S., Smith, Z., Abouhassan, A., Ayar, C., Jaber, N. A., Clarke, A. W., Commissaris, R. L., & Jaber, L. A. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010367653 · Cited by 18
“Ethnicity, n (%)* Caucasian 12 (60) 8 (89) 4 (36) Asian 5 (25) 0 (0) 5 (46) Other 3 (15) 1 (11) 2 (18) Education, n (%) College students 19 (95) 8 (89) 11 (100)”
Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies
Giorgino, F., Leonardini, A., Natalicchio, A., & Laviola, L. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346698 · Cited by 18
Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis
Kissow, H. (2015) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000132 · Cited by 18
“In addition, GLP-1 has been shown to reduce food intake in rodents [24,25] and in healthy [26,27], obese [28,29], and diabetic [30] humans, revealing the enormous therapeutic potential of this peptide.”
BackgroundDuraisamy, A. J., Bayen, S., Saini, S., Sharma, A. K., Vats, P., & Singh, S. B. (2015) · Endokrynologia Polska · doi:10.5603/ep.2015.0043 · Cited by 17
“It is an anorectic peptide that suppresses food intake upon peripheral administration [14].”
BackgroundVedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 19
Clapcote, S. J. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-58811-7_5 · Cited by 18
Pan, W. Q., Zhang, Y., Zeng, C., Xu, F. L., Yan, J., & Weng, J. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6453 · Cited by 23
“Furthermore, recent studies have indicated that GLP‑1 reduces food intake by interacting with the hypothalamus (18,19).”
Basolo, A., Heinitz, S., Stinson, E. J., Begaye, B., Hohenadel, M. G., Piaggi, P., Krakoff, J. A., & Votruba, S. B. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0954-5 · Cited by 17
Sánchez-Torralvo, F. J., Pedreño, L. V., Marín, M. G., Tapia, M. J., Lima, F., García‐Fuentes, E., García, P. C., Ruiz, J. M., Cañete, A. R., Valdés, S., et al. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.10.008 · Cited by 19
Mucosal and hormonal adaptations after Roux-en-Y gastric bypass
Feris, F., MCRAE, A. N., Kellogg, T. A., McKenzie, T. J., Ghanem, O. M., & Acosta, A. J. (2022) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2022.08.020 · Cited by 22
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.010 · Cited by 20
Ullrich, S. S., Otto, B., Hutchison, A. T., Luscombe‐Marsh, N. D., Horowitz, M., & Feinle‐Bisset, C. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00504.2014 · Cited by 18
Ranganath, L. R., Schäper, F., Gama, R. M., Morgan, L. D., Wright, J., Teale, D., & Marks, V. (1999) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(199911/12)15:6<390::aid-dmrr67>3.0.co;2-w · Cited by 20
“In addition to stimulating insulin, GLP-1 may also have an important role in satiety [23,24].”
BackgroundKapitza, C., Zdravkovic, M., Zijlstra, E., Segel, S., Heise, T., & Flint, A. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010374474 · Cited by 17
“GLP-1 also decreases blood glucagon levels and reduces gastric emptying, decreases gastric motility, and reduces hunger and energy intake.(2,3) In animal models, GLP-1 has been shown to promote β-cell growth and rescue.”
BackgroundSelf-citationPatient initiation and maintenance of GLP-1 RAs for treatment of obesity
Patel, D., & Smith, A. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1947796 · Cited by 16
New drug therapies for metabolic dysfunction-associated steatohepatitis
Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 19
Yang, M., Jia, M., Cai, M., Feng, X., Huang, L., & Yang, J. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06840-9 · Cited by 18
“When physi - ological doses of GLP-1 are administered intravenously during meals, subjects experience increased satiety and reduced food intake (Flint et al. 1998).”
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
Peripheral Signals Mediate the Beneficial Effects of Gastric Surgery in Obesity
Barja-Fernández, S., Folgueira, C., Castelao, C., Leis, R., Casanueva, F. F., & Seoane, L. M. (2015) · Gastroenterology Research and Practice · doi:10.1155/2015/560938 · Cited by 16
“In addition, the enteric nervous system comprises a set of neurons localized in gastric myenteric and submucous plexus required for different gastrointestinal functions as secretion [18] but also primarily involved in responding to nutrient signalling [19].”
BackgroundBray, G. A., & Ryan, D. H. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.08.013 · Cited by 21
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
“suppression of appetite by increasing the perception of fullness and satiety [96].”
BackgroundBremholm, L., Andersen, U. B., Hornum, M., Hilsted, L., Veedfald, S., Hartmann, B., & Holst, J. J. (2017) · Physiological Reports · doi:10.14814/phy2.13102 · Cited by 20
“Thus, it inhibits appetite, and thereby food intake (Flint et al. 1998), which is expedient considering the association between obesity and type 2 diabetes, and a GLP-1 receptor agonist has recently been approved for the therapy of obesity (Pi-Sunyer et al.”
BackgroundSelf-citationHyde, K. M., Blonde, G. D., le Roux, C. W., & Spector, A. C. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.03.045 · Cited by 16
Kakouri, A., Kanti, G., Kapantais, E., Kokkinos, A. D., Lanaras, L., Farajian, P., Galanakis, C., Georgantopoulos, G., Vlahos, N., Mastorakos, G. P., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14090869 · Cited by 18
“GLP-1 results in enhanced insulin secretion [42] and GIP stimulates insulin secretion by β-pancreatic cells in a glucose-dependent manner [43].”
BackgroundColvin, K. J., Killen, H. S., Kanter, M. J., Halperin, M. C., Engel, L., Dickinson, M., Fimmel, A. I., Holland, J. G., & Currie, P. J. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113726 · Cited by 16
Infant appetite traits, feeding practices and child obesity in low‐income Hispanic families
Vandyousefi, S., Messito, M. J., Katzow, M. W., Scott, M. A., & Gross, R. S. (2022) · Pediatric Obesity · doi:10.1111/ijpo.12913 · Cited by 16
“peptide YY levels than their formula-fed counterparts, which inhibit gastric acid secretion and emptying and suppress energy intake through the sensation of satiety.(45,47) It is shown that both”
BackgroundHealthy Sleep Every Day Keeps the Doctor Away
Feingold, C. L., & Smiley, A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191710740 · Cited by 23
“Importantly, it is also known to promote feelings of satiety, similar to leptin [27].”
BackgroundHarada, K., Kitaguchi, T., & Tsuboi, T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.03.151 · Cited by 16
Clayton, D. J., Creese, M., Skidmore, N., Stensel, D. J., & James, L. J. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.106 · Cited by 16
PICK1 is essential for insulin production and the maintenance of glucose homeostasis
Li, J., Mao, Z., Huang, J., & Xia, J. (2018) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-03-0204 · Cited by 18
“Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced in enteroendocrine L cells of the gut, which can directly activate pancreatic β cells and augment its glucose-induced insulin secretion in a cAMP-dependent pathway (Orskov, 1992; Flint et al., 1998).”
BackgroundGenetic variation inGlp1rexpression influences the rate of gastric emptying in mice
Kumar, K. G., Byerley, L. O., Vólaufová, J., Drucker, D. J., Churchill, G. A., Li, R., York, B., Zuberi, A. R., & Richards, B. K. S. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00640.2007 · Cited by 17
“Effects of exendin-(9-39) on gastric emptying.”
BackgroundMethodInfluentialLarsen, M. O., Rolin, B., Ribel, U., Wilken, M., Deacon, C. F., Svendsen, O., Gotfredsen, C. F., & Carr, R. D. (2003) · Journal of Diabetes Research · doi:10.1155/edr.2003.93 · Cited by 21
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“Meal-induced physiological GLP-1 secretion, as well as pharmacological administration of GLP-1R agonists, promote negative energy balance by reducing food intake [38–41], an effect that is maintained in patients with obesity [42].”
Douros, J. D., Flak, J. N., & Knerr, P. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1530985 · Cited by 18
Jensen, M. N., Israelsen, I. M. E., Wardman, J. H., Jensen, D. B., Andersen, D. B., Toft‐Bertelsen, T. L., Rath, M. F., Holst, J. J., ROSENKILDE, M. M., & MacAulay, N. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00652-x · Cited by 18
“It was later demonstrated to promote food satiety and weight loss [6–8], possibly via intracerebral actions of GLP-1 [9–11].”
Self-citationWeighing in on Whole Grains: A Review of Evidence Linking Whole Grains to Body Weight
McKeown, N. M., Hruby, A., Saltzman, E. J., Choumenkovitch, S. F., & Jacques, P. F. (2012) · Cereal Foods World · doi:10.1094/cfw-57-1-0020 · Cited by 16
“PYY and GLP-1 are important modulators of food intake that affect gastric emptying (37); in addition, GLP-1 acts as an incretin hormone (10).”
BackgroundSridhar, V. S., Dubrofsky, L., Boulet, J., & Cherney, D. Z. I. (2020) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2020-0100 · Cited by 24
“A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.”
MethodDiscovery of the GI Effects of GLP-1: An Historical Perspective
Holst, J. J. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07519-3 · Cited by 15
“In further studies, we therefore infused physiological amounts of GLP-1 intravenously while measuring appetite and food intake in humans [36], demonstrating significant inhibition of hunger and increases in satiety and fullness, with decreased food intake observed at a later ad libitum meal.”
MethodSelf-citationType 2 diabetes mellitus: time to change the concept
Levit, S., Philippov, Y. I., & Gorelyshev, A. (2013) · Diabetes Mellitus · doi:10.14341/2072-0351-3603 · Cited by 24
“ГПП-1 снижает потребность в инсулине (а, следовательно, и нагрузку на β-клетки): • регулируя скорость опорожнения желудка, обеспечивая более равномерное поступление и всасывание пищи в кишечнике, что позволяет снизить пиковую концентрацию глюкозы в крови [17, 19]; • подавляя постпрандиальную секрецию глюкагона α-клетк…”
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
Hansen, J., Brock, B., Bøtker, H. E., GJEDDE, A. H., Rungby, J., & Gejl, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9286-8 · Cited by 16
“Thus GLP1 promotes satiety and suppresses fuel intake in humans [28, 29].”
Plasma levels of glucagon‐like peptide 1 and markers of obesity among young and healthy adults
van der Stouwe, J. G., Aeschbacher, S., Krisai, P., Schoen, T., Meyre, P. B., Todd, J., Estis, J., Risch, M., Risch, L., & Conen, D. (2015) · Clinical Endocrinology · doi:10.1111/cen.12789 · Cited by 18
Review: DPP IV inhibitors - current evidence and future directions
Vilsbøll, T., & Knop, F. K. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070020401 · Cited by 17
Peters, H. P. F., & Mela, D. J. (2008) · CRC Press eBooks · doi:10.1201/9781420047844.ch10 · Cited by 16
Roges, O. A., Baron, M., & Philis‐Tsimikas, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.705 · Cited by 15
“Peripheral GLP-1 administration increased satiety and reduced appetite by 12% when compared with saline in a placebo-controlled study [99].”
BackgroundTherapeutic management of posttransplant diabetes mellitus
Mannon, R. B. (2008) · Transplantation Reviews · doi:10.1016/j.trre.2007.12.003 · Cited by 17
“6 kg) in 1 year [61], primarily by its direct effect on suppressing food intake seen in both rodents [62] and man [63].”
BackgroundA look on food intake and satiety: from humans to rodent models
Costa, D. G., Almeida, C., Cavadas, C., & Carmo‐Silva, S. (2022) · Nutrition Reviews · doi:10.1093/nutrit/nuac010 · Cited by 17
G protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
Kenkre, J. S., Tan, T., & Bloom, S. R. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.13.5 · Cited by 17
ŠEBÖKOVÁ, E., Benardeau, A. M., Sprecher, U., Sewing, S., Tobalina, L., & Migliorini, C. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01207.x · Cited by 15
“In humans, GLP-1 reduces food intake by inhibiting gastric emptying [29] and inducing satiety [30].”
BackgroundAlbèr, A., Brønden, A., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12911 · Cited by 14
Crabtree, D. R., Buosi, W., Fyfe, C., Horgan, G. W., Μanios, Y., Androutsos, O., Giannopoulou, A., Finlayson, G., Beaulieu, K., Meek, C. L., et al. (2020) · Nutrients · doi:10.3390/nu12123710 · Cited by 15
Self-citationElekofehinti, O. O. (2022) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-022-00282-0 · Cited by 14
“GLP-1 analogues have been used to treat patients with diabetes because they reduce energy intake in people [32, 33].”
BackgroundNeuroendocrine regulation of hunger, satiety and maintenance of energy balance
González-Hita, M. E., Macias, K. G. A., & Enríquez, S. S. (2006) · Investigación en Salud · Cited by 28
Liraglutide: effects beyond glycaemic control in diabetes treatment
McGill, J. B. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02495.x · Cited by 15
Incretin hormones and beta cell function in chronic pancreatitis.
Knop, F. K. (2010) · PubMed · Cited by 17
Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents
Walter, C. P., Bleske, B. E., & Dorsch, M. P. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12177 · Cited by 18
“Small studies have demonstrated GLP-1 receptor agonists have the potential to increase satiety, decrease food intake, and induce weight loss.(60,61) However, emerging evidence suggests these agents have potential for cardiovascular benets beyond blood glucose control and weight loss as well.”
BackgroundKotsis, V., Jordan, J., Stabouli, S., Antza, C., Micić, D., Jelaković, B., Schlaich, M. P., Nilsson, P. M., Kreutz, R. H., Mancia, G., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002279 · Cited by 15
Obesity‐Related Hormones in Low‐Income Preschool‐Age Children: Implications for School Readiness
Miller, A. L., Lumeng, C. N.-K., DelProposto, J. L., Florek, B., Wendorf, K., & Lumeng, J. C. (2013) · Mind Brain and Education · doi:10.1111/mbe.12034 · Cited by 18
Kehlet, U., Kofod, J., Holst, J. J., Ritz, C., Aaslyng, M. D., & Raben, A. (2017) · Journal of Nutrition · doi:10.3945/jn.117.250332 · Cited by 16
Self-citationGut peptides before and following Roux‐En‐Y gastric bypass: A systematic review and meta‐analysis
Simoneau, M., McKay, B., Brooks, E., Doucet, É., & Baillot, A. (2024) · Obesity Reviews · doi:10.1111/obr.13702 · Cited by 14
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“GLP-1R agonists reduce food intake in humans as well as in animal models (e.g., Flint et al. 1998; Wilding et al. 2021; Williams, Baskin, and Schwartz 2009).”
Mottalib, A., Abrahamson, M. J., POBER, D. M., Polak, R., Eldib, A. H., Tomah, S., Ashrafzadeh, S., & Hamdy, O. (2019) · Nutrition and Diabetes · doi:10.1038/s41387-019-0093-x · Cited by 16
Lundgren, J. R., Færch, K., Witte, D. R., Jonsson, A. E., Pedersen, O. B., Hansen, T. F., Lauritzen, T., Holst, J. J., Vistisen, D., Jørgensen, M. E., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0937-7 · Cited by 14
Self-citationHilkens, L., Praster, F., van Overdam, J., Nyakayiru, J., Singh‐Povel, C. M., Bons, J. A. P., van Loon, L. J. C., & van Dijk, J. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.12.012 · Cited by 16
Lee, C., Kim, A.-Y., Pyun, C., Fukushima, M., & Han, K. (2013) · Food Science and Biotechnology · doi:10.1007/s10068-014-0036-1 · Cited by 13
Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes
Wick, A., & Newlin, K. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00455.x · Cited by 13
Gastrointestinal Issues in the Older Female Patient
Zuchelli, T. E., & Myers, S. E. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.03.007 · Cited by 14
Nakamaru, Y., Hayashi, Y., Sekine, M., Kinoshita, S., Thompson, J., Kawaguchi, A., Davies, M., Heuer, H. J., Yamazaki, H., & Akimoto, K. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.03.002 · Cited by 13
Nakamaru, Y., Hayashi, Y., Davies, M., Heuer, H. J., Hisanaga, N., & Akimoto, K. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.06.012 · Cited by 14
Simonds, S. E., Pryor, J. T., Koegler, F. H., Buch-Rasmussen, A. S., Kelly, L. E., Grove, K. L., & Cowley, M. A. (2019) · Diabetes · doi:10.2337/db18-1149 · Cited by 13
Witte, A.-B., Hilsted, L. M., Holst, J. J., & Schmidt, P. T. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1101780 · Cited by 14
Self-citationGut peptide hormones: Importance for food intake
Näslund, E. B., Schmidt, P. T., & Hellström, P. M. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410010634 · Cited by 13
“[70] Flint A, Raben A, Astrup A, Holst JJ.”
BackgroundDevelopment of minimally invasive techniques for management of medically-complicated obesity
Rashti, F., Gupta, E., Ebrahimi, S., Shope, T. R., Koch, T. R., & Gostout, C. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i37.13424 · Cited by 13
Metadata
- Authors
- Flint, A., Raben, A., Astrup, A., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-02-01
- Volume
- 101
- Issue
- 3
- Pages
- 515-520
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508592
- OpenAlex
- W1975756049
- Cited by
- 1,402
- References
- 40
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 62 · 2023: 33 · 2022: 55 · 2021: 53 · 2020: 49 · 2019: 44 · 2018: 52 · 2017: 49 · 2016: 54 · 2015: 59 · 2014: 64 · 2013: 74 · 2012: 72
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- glucagon-like peptide-1, satiety, appetite, energy intake, insulin, glucagon, blood glucose, appetite regulation, intravenous infusion
- MeSH terms
- Adult, Appetite, Appetite Depressants, Appetite Regulation, Blood Glucose, Energy Intake, Glucagon, Humans, Insulin, Male, Pain Measurement, Peptide Fragments, Protein Precursors, Satiation, Cross-Over Studies, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.